Haisco Pharmaceutical Group's high P/E ratio is concerning due to its poor earnings forecast. The inflated P/E from recent momentum may not be sustainable, posing a risk to shareholders and potential investors.
Haisco Pharmaceutical Group's slower EPS growth compared to its share price growth suggests future earnings growth is key for potential investors. The company's high P/E ratio indicates market optimism.
Analysts anticipate growth in future earnings despite mixed fundamentals, shrinking profits. Uncertainty for investors due to low ROE, lack of dividends.
Haisco Pharmaceutical Group Stock Forum
No comment yet